patent/CN-102516099-A

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1cc134e139490e374ccf80c05d94857
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-08
filingDate	2011-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efa3692fe670582e72c46520d4483a17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bef361b9cf314d890b94aaa428a5ecf9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8b4e57373bfe45f568c3bb5f00f94ee
publicationDate	2012-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-102516099-A
titleOfInvention	A kind of derivative of water-soluble triolamine
abstract	The present invention provides a brand-new derivative of triolamine with strong water solubility and is more suitable for clinical use, that is, propofol prodrug. After the compound enters the human body, it can be hydrolyzed to release propofol quickly, prolonging the anesthesia effect time, effectively overcome the disadvantage of poor water solubility of propofol.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109651177-A
priorityDate	2011-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008161400-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004220283-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467356864 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467361764

Total number of triples: 18.